Sethuraman Natarajan's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed Nov 6, 2024
- Accession no.
- 0001689375-24-000064
- Filed
- Nov 6, 2024
- Trade date
- Nov 4-6, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $339.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sethuraman NatarajanCIK 0001873394 | Officer (President, Research & Develop.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 4, 2024 | Common Stock | SSaleDisposed | −749 | $18.02 | −$13,496.98 | 182,467 | Direct | |
| Nov 5, 2024 | Common Stock | SSaleDisposed | −5,171 | $18.18 | −$94,008.78 | 177,296 | Direct | |
| Nov 6, 2024 | Common Stock | SSaleDisposed | −9,554 | $18.71 | −$178,755.34 | 167,742 | Direct | |
| Nov 6, 2024 | Common Stock | SSaleDisposed | −2,745 | $19.32 | −$53,033.4 | 164,997 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.